Every material Form 8-K Aardvark Therapeutics, Inc. has filed with the SEC since October 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aardvark Therapeutics reported exploratory efficacy and safety data from its previously terminated Phase 3 HERO trial and open-label extension, which the company says are directionally consistent with continued development of ARD-101 for Prader-Willi syndrome. The company states the partial data are not sufficient to draw definitive conclusions, the HERO trial was stopped early, and the FDA has lifted the clinical hold, so the company plans to request an FDA meeting on a new Phase 3 design.
HERO trial was terminated early with 67 of 90 planned participants randomized; all efficacy data are considered exploratory
OLE participants who switched from placebo to ARD-101 had an observed average 6-point reduction in HQ-CT score
One Grade 4 cardiac serious adverse event occurred at 800 mg twice daily with pitolisant, which the FDA concurred is related to a drug-drug interaction
FDA lifted the clinical hold on October 22, 2026; the company expects to resume PWS clinical activities in 2027
The FDA lifted the clinical hold on the Investigational New Drug application for Aardvark's ARD-101 for hyperphagia in Prader-Willi Syndrome, and Aardvark said clinical development may resume. Resumption still depends on further engagement with the FDA on the Phase 3 trial design, and the company describes the Phase 3 HERO trial and its open-label extension as terminated.
FDA lifted the clinical hold on the ARD-101 IND, following a hold placed in May 2026 on the HERO and OLE trials
Dosing in the HERO trial was voluntarily paused on February 27, 2026 after reversible ECG changes in a separate healthy-volunteer study
A recent ECG study observed no cardiac events at ARD-101 doses of 200 mg and 400 mg twice daily
Aardvark will host a webcast on October 23, 2026 at 8:00 a.m. ET to review exploratory Phase 3 HERO and OLE data
Aardvark Therapeutics appointed David Zhang as a Class II director effective October 7, 2026, and announced the appointment in a press release dated October 8, 2026. The company describes him as an independent director and says he will help navigate the regulatory path for ARD-101 and shape its next phase of development for Prader-Willi Syndrome.
Appointed by the board on October 6, 2026, effective October 7, 2026, as a Class II director
Non-employee director cash compensation of $40,000 per year, prorated for time served
Option grant on October 7, 2026 sized at $500,000, vesting monthly over 36 months
Dr. Zhang is Chief Strategy Officer of Abivax S.A.; previously held roles at Alumis Inc. and MyoKardia, Inc.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aardvark Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →